Iovance Biotherapeutics received FDA IND clearance for IOV-5001, a next-generation tumor-infiltrating lymphocyte (TIL) therapy engineered with an interleukin-12 (IL-12) tethering component. The clearance supports clinical advancement under the company’s planned development pathway. The approach aims to enhance TIL function by tethering IL-12, potentially improving immune activity in the tumor microenvironment while using TIL as the cellular backbone. The provided excerpt does not specify the tumor indication or trial timing. IND clearance remains a key gating event for cellular immunotherapies, where manufacturing complexity and patient selection protocols can drive both clinical outcomes and scalability.